{"id":6045,"date":"2026-05-06T10:44:26","date_gmt":"2026-05-06T17:44:26","guid":{"rendered":"https:\/\/www.iths.org\/participate\/?p=6045"},"modified":"2026-05-06T10:44:26","modified_gmt":"2026-05-06T17:44:26","slug":"safeguard","status":"publish","type":"post","link":"https:\/\/www.iths.org\/participate\/safeguard\/","title":{"rendered":"SAFEGUARD"},"content":{"rendered":"

[vc_row css_animation=”” row_type=”row” use_row_as_full_screen_section=”no” type=”full_width” angled_section=”no” text_align=”left” background_image_as_pattern=”without_pattern”][vc_column][vc_column_text css=””]<\/p>\n

<\/div>\n

The SAFEGUARD study will evaluate the safety and efficacy of an investigational medicine called SAB-142 in delaying disease progression in people newly diagnosed with T1D.<\/p>\n

For more information visit: https:\/\/clinicaltrials.gov\/study\/NCT07187531<\/a><\/p>\n

Participant Eligibility<\/h3>\n

Eligibility includes:
\n-12 to 40 years old
\n-T1D diagnosis within the past three months<\/p>\n

Contact<\/h3>\n

The Outreach Team
\n(800) 888-4187<\/p>\n

\n

Additional Study Details<\/h3>\n

Full Study Title<\/strong>
\nSAFety and Efficacy of Human Anti-thymocyte ImmunoGlobUlin SAB-142 ARresting Progression of Type 1 Diabetes
\n<\/span><\/p>\n

Study ID:<\/strong> IRB06096<\/div>\n
ClinicalTrials.gov Link:<\/strong> NCT07187531<\/a><\/div>\n
<\/div>\n
Start Date:<\/strong> 11\/25\/2025<\/div>\n
End Date:<\/strong> 12\/31\/2028<\/div>\n
<\/div>\n

Investigator(s)<\/strong>
\nDr. Kurt Griffin kgriffin@benaroyaresearch.org<\/a>
\nDr. Sandra Lord SLord@benaroyaresearch.org<\/a><\/span><\/p>\n

Please contact the outreach team with questions<\/p>\n

Accepts Healthy Volunteers?<\/strong>
\nNo<\/span><\/p>\n

Study Site(s)<\/strong><\/p>\n

\n

Benaroya Research Institute<\/h4>\n

1201 Ninth Ave.
\nSeattle, Washington 98101<\/p>\n<\/div>\n

\n

<\/h4>\n<\/div>\n
<\/div>\n

<\/div>[\/vc_column_text][\/vc_column][\/vc_row]<\/p>\n<\/div>","protected":false},"excerpt":{"rendered":"

[vc_row css_animation=”” row_type=”row” use_row_as_full_screen_section=”no” type=”full_width” angled_section=”no” text_align=”left” background_image_as_pattern=”without_pattern”][vc_column][vc_column_text css=””] The SAFEGUARD study will evaluate the safety and efficacy of an investigational medicine called SAB-142 in delaying disease progression in people newly diagnosed with T1D. For more information visit: https:\/\/clinicaltrials.gov\/study\/NCT07187531 Participant Eligibility Eligibility includes: -12 to…<\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[9],"tags":[393],"class_list":["post-6045","post","type-post","status-publish","format-standard","hentry","category-diabetes","tag-t1d"],"_links":{"self":[{"href":"https:\/\/www.iths.org\/participate\/wp-json\/wp\/v2\/posts\/6045","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.iths.org\/participate\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.iths.org\/participate\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.iths.org\/participate\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.iths.org\/participate\/wp-json\/wp\/v2\/comments?post=6045"}],"version-history":[{"count":3,"href":"https:\/\/www.iths.org\/participate\/wp-json\/wp\/v2\/posts\/6045\/revisions"}],"predecessor-version":[{"id":6048,"href":"https:\/\/www.iths.org\/participate\/wp-json\/wp\/v2\/posts\/6045\/revisions\/6048"}],"wp:attachment":[{"href":"https:\/\/www.iths.org\/participate\/wp-json\/wp\/v2\/media?parent=6045"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.iths.org\/participate\/wp-json\/wp\/v2\/categories?post=6045"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.iths.org\/participate\/wp-json\/wp\/v2\/tags?post=6045"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}